Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Generic Clearance for the Collection of Qualitative Data on Tobacco Products and Communications, 44357 [2015-18295]
Download as PDF
Federal Register / Vol. 80, No. 143 / Monday, July 27, 2015 / Notices
44357
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
International Panel Physicians (All sites).
TB Indicators Excel Spreadsheet.
TOTAL ..........................
353
..............................................
..............................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–18301 Filed 7–24–15; 8:45 am]
BILLING CODE 4163–18–P
................................
0910–0796. The approval expires on
June 30, 2018. A copy of the supporting
statement for this information collection
is available on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
Dated: July 22, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–18295 Filed 7–24–15; 8:45 am]
BILLING CODE 4164–01–P
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Generic Clearance for the Collection of
Qualitative Data on Tobacco Products
and Communications
AGENCY:
Food and Drug Administration,
ACTION:
[Docket No. FDA–2014–D–0103]
Analytical Procedures and Methods
Validation for Drugs and Biologics;
Guidance for Industry; Availability
AGENCY:
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled,
‘‘Generic Clearance for the Collection of
Qualitative Data on Tobacco Products
and Communications’’ has been
approved by the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On
December 10, 2014, the Agency
submitted a proposed collection of
information entitled, ‘‘Generic
Clearance for the Collection of
Qualitative Data on Tobacco Products
and Communications’’ to OMB for
review and clearance under 44 U.S.C.
3507. An Agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number. OMB has now
approved the information collection and
has assigned OMB control number
SUMMARY:
tkelley on DSK3SPTVN1PROD with NOTICES
Food and Drug Administration
Food and Drug Administration,
HHS.
HHS.
VerDate Sep<11>2014
18:58 Jul 24, 2015
Jkt 235001
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘Analytical Procedures and
Methods Validation for Drugs and
Biologics.’’ This guidance supersedes
the draft of the same name that
published on February 19, 2014, and
replaces the 2000 draft guidance for
industry on ‘‘Analytical Procedures and
Methods Validation’’ and the 1987 FDA
guidance for industry on ‘‘Submitting
Samples and Analytical Data for
Methods Validation.’’ This guidance
discusses how to submit analytical
procedures and methods validation data
to support the documentation of the
identity, strength, quality, purity, and
potency of drug substances and drug
products.
DATES: Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Office of Communications, Division of
Drug Information, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Hillandale Bldg., 4th
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Total burden
hours
7.5
2,648
..............................
2,648
1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2014–N–0987]
Average
burden
per response
(in hours)
Number of
responses per
respondent
Number of
respondents
Type of respondents
Floor, Silver Spring, MD 20993, or to
the Office of Communication, Outreach
and Development, Center for Biologics
Evaluation and Research (CBER), Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. The guidance may also be
obtained by mail by calling CBER at
1–800–835–4709 or 240–402–7800. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Room 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Lucinda Buhse, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 2130,
Silver Spring, MD 20993–0002, 240–
402–4595, or Stephen Ripley, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
7301, Silver Spring, MD 20993–0002,
240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance for industry entitled
‘‘Analytical Procedures and Methods
Validation for Drugs and Biologics.’’
This guidance supersedes the draft of
the same name that published on
February 19, 2014, and replaces the
2000 draft guidance for industry on
‘‘Analytical Procedures and Methods
Validation’’ and the 1987 FDA guidance
for industry on ‘‘Submitting Samples
and Analytical Data for Methods
Validation.’’ It discusses how to submit
analytical procedures and methods
validation data to support the
documentation of the identity, strength,
quality, purity, and potency of drug
substances and drug products, and how
to assemble information and present
E:\FR\FM\27JYN1.SGM
27JYN1
Agencies
[Federal Register Volume 80, Number 143 (Monday, July 27, 2015)]
[Notices]
[Page 44357]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18295]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0987]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Generic Clearance for the Collection
of Qualitative Data on Tobacco Products and Communications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled, ``Generic Clearance for the
Collection of Qualitative Data on Tobacco Products and Communications''
has been approved by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On December 10, 2014, the Agency submitted a
proposed collection of information entitled, ``Generic Clearance for
the Collection of Qualitative Data on Tobacco Products and
Communications'' to OMB for review and clearance under 44 U.S.C. 3507.
An Agency may not conduct or sponsor, and a person is not required to
respond to, a collection of information unless it displays a currently
valid OMB control number. OMB has now approved the information
collection and has assigned OMB control number 0910-0796. The approval
expires on June 30, 2018. A copy of the supporting statement for this
information collection is available on the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: July 22, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-18295 Filed 7-24-15; 8:45 am]
BILLING CODE 4164-01-P